Bioinformatics analysis of gene expression data for the identification of critical genes in breast invasive carcinoma

YI LI and YONGSHENG WANG

Department of Thoracic Oncology, Cancer Center, and State Key Laboratory of Biotherapy/Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610000, P.R. China

Received December 26, 2016; Accepted July 20, 2017

DOI: 10.3892/mmr.2017.7717

Abstract. Gene expression data were analyzed in order to identify critical genes in breast invasive carcinoma (BRCA). Data from 1,073 BRCA samples and 99 normal samples were analyzed, which were obtained from The Cancer Genome Atlas. Differentially expressed genes (DEGs) were identified using the significance analysis of microarrays method and a functional enrichment analysis was performed using the Database for Annotation, Visualization and Integrated Discovery. Relevant microRNAs (miRNAs), transcription factors (TFs) and associated small molecule drugs were revealed by Fisher's exact test. Furthermore, protein-protein interaction (PPI) information was downloaded from the Human Protein Reference Database. Interactions with a Pearson’s correlation coefficient >0.5 were identified and PPI networks were subsequently constructed. A survival analysis was also conducted according to the Kaplan-Meier method. Initially, the 1,073 BRCA samples were clustered into seven groups, and 5,394 DEGs that were identified in ≥4 groups were selected. These DEGs were involved in the cell cycle, ubiquitin-mediated proteolysis, oxidative phosphorylation and human immunodeficiency virus infection. In addition, TFs, including Sp1 transcription factor, DAN domain BMP antagonist family member 5, MYCN proto-oncogene, bHLH transcription factor and cAMP responsive element binding protein (CREB)1, were identified in the BRCA groups. Seven PPI networks were subsequently constructed and the top 10 hub genes were acquired, including KB transcriptional corepressor 1, inhibitor of nuclear factor (NF)-κB kinase subunit γ, NF-κB subunit 2, transporter 1, ATP binding cassette subfamily B member, CREB binding protein and proteasome subunit α3. A significant difference in survival was observed between the two combined groups (groups-2, -4 and -5 vs. groups-1, -3, -6 and -7). In conclusion, numerous critical genes were detected in BRCA, and relevant miRNAs, TFs and small molecule drugs were identified. These findings may advance understanding regarding the pathogenesis of BRCA.

Introduction

Breast cancer is the most common cancer in women, affecting ~12% of women worldwide (1). It is also the leading cause of cancer-associated mortality in women (2,3). The main cause of breast cancer mortality is metastasis, which accounts for ~90% of breast cancer-associated mortality (4,5). Therefore, research has focused on breast cancer metastasis. The treatment methods of breast cancer include surgery, radiation, chemotherapy, hormone blocking therapy (6), and monoclonal antibodies (7). The choice of treatment for breast cancer depends on classification and special markers. Breast cancers are classified by several grading systems, such as histopathology, grade, stage, receptor status, and protein and gene expression patterns (8).

Various signaling pathways have been implicated in metastasis regulation, including transforming growth factor-β signaling (9), Wnt signaling (10), Notch signaling (11) and epidermal growth factor signaling (12). Numerous metastasis-associated biomarkers have also been revealed. Parathyroid hormone-related protein (12-48) is a plasma biomarker that is associated with breast cancer bone metastasis (13). In addition, C-C chemokine receptor type 7 and C-X-C chemokine receptor type 4 are biomarkers that exhibit predictive value for axillary lymph node metastasis in breast cancer (14). MicroRNAs (miRNAs/miRs) serve important roles in the regulation of metastasis, including miR-31 (15) and miR-146 (16). Due to its complexity and heterogeneity, the molecular mechanisms underlying breast invasive carcinoma (BRCA) have yet to be completely elucidated. The identification of critical genes is an essential step toward fully understanding the metastatic mechanism of BRCA and may also provide novel therapeutic targets against BRCA.

In the present study, BRCA gene expression data were acquired from The Cancer Genome Atlas (TCGA). Differential analysis, combined with network analysis, was performed to identify the critical genes in BRCA. In addition, relevant miRNAs, transcription factors (TFs) and associated small
molecule drugs were investigated, which may provide information that aids the development of therapeutic strategies.

Materials and methods

Raw data and pretreatment. RNA-seq data for BRCA were downloaded from TCGA (https://cancergenome.nih.gov/) using TCGA-Assembler (17); the data were then normalized with package TCC (http://www.bioconductor.org/packages/release/bioc/html/TCC.html). Data from 1,073 BRCA samples and 99 normal samples, which were downloaded from TCGA, were included for further analysis. The RNA-seq data was acquired from the platform Illumina HiSeq 2000 RNA Sequencing. The survival data were also collected from TCGA. Missing values were filled with ‘1’ and a log2 transformation was applied. BRCA samples were clustered using Algorithms and Framework for Nonnegative Matrix Factorization (NMF; https://cran.r-project.org/web/packages/NMF/index.html) (18) and k value was set to generate optimal cophenetic correlation coefficient (19).

Screening of differentially expressed genes (DEGs). DEGs were identified using the significance analysis of microarrays method (20), which compensates for the false discovery rate in multiple testing. Adjusted $P<0.05$ and $\log$ (fold change) $<1$ were set as the cut-off criteria.

Functional enrichment analysis. Gene Ontology enrichment analysis and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis were performed using the Database for Annotation, Visualization and Integration Discovery (http://david.abcc.ncifcrf.gov/) (21). The P-value was adjusted by Bonferroni correction (22). Reactome analysis were performed using the Reactome Database (http://reactome.org/) (23).

Screening of relevant miRNAs, TFs and associated drugs. Regulatory relationships between miRNAs and target genes, and between TFs and target genes were downloaded from combinatorial Gene Regulatory Networks Builder (https://www.scbit.org/cgrnb/) (24,25). A total of 197,906 miRNA-target gene relationships were acquired, which included 699 mature miRNAs and 8,646 target genes. Furthermore, 210,637 TF-target gene relationships were obtained, which included 207 TFs and 16,862 target genes.

Relationships between small molecule drugs and target genes were downloaded from DrugBank (http://www.drugbank.ca/). A total of 6,108 relationships were acquired, which included 348 small molecule drugs and 1,353 target genes.

Relevant miRNAs, TFs and drugs were identified by Fisher’s exact test (26). For specific miRNAs, TFs or drugs the associated target genes were defined as $M$, whereas the DEGs were identified as $N$. The significance of the overlap between $M$ and $N$ was examined by Fisher’s exact test: Where ‘a’ indicates genes included in $M$ and $N$, ‘d’ indicates genes included in neither $M$ nor $N$, ‘b’ indicates genes only included in $M$, and ‘c’ indicates genes only included in $N$. Relevant miRNAs, TFs and drugs with $P<0.05$ were selected for each group of BRCA samples.

Construction of interaction networks. Protein-protein interaction (PPI) information was downloaded from the Human Protein Reference Database (http://www.hprd.org/) (27). A total of 39,240 PPI interactions and 9,572 proteins were identified. Interactions with a Pearson’s correlation coefficient $>0.5$ were selected and PPI networks were subsequently constructed.

Survival analysis. Difference in survival time among the various BRCA groups was analyzed using the Kaplan-Meier (K-M) method in the survival package (version 2.41-3; https://cran.r-project.org/web/packages/survival/index.html).

Results

Classification of BRCA samples. Box plots of normalized gene expression data are presented in Fig. 1. A good performance of normalization was achieved.

Protein Reference Database (http://www.hprd.org/) (27). A total of 39,240 PPI interactions and 9,572 proteins were identified. Interactions with a Pearson’s correlation coefficient $>0.5$ were selected and PPI networks were subsequently constructed.

Screening of relevant miRNAs, TFs and associated drugs. Regulatory relationships between miRNAs and target genes, and between TFs and target genes were downloaded from combinatorial Gene Regulatory Networks Builder (https://www.scbit.org/cgrnb/) (24,25). A total of 197,906 miRNA-target gene relationships were acquired, which included 699 mature miRNAs and 8,646 target genes. Furthermore, 210,637 TF-target gene relationships were obtained, which included 207 TFs and 16,862 target genes.

Classification of BRCA samples. Box plots of normalized gene expression data are presented in Fig. 1. A good performance of normalization was achieved.

Classification of BRCA samples. Box plots of normalized gene expression data are presented in Fig. 1. A good performance of normalization was achieved.

DEGs and biological functions. The DEGs were identified in the BRCA group samples compared with the control samples. A total of 4,970 DEGs were identified in group-1, 6,355 DEGs in group-2, 6,008 DEGs in group-3, 5,018 DEGs in group-4, 7,793 DEGs in group-5, 4,976 DEGs in group-6 and 3,581 DEGs in group-7 compared with the control samples. A considerable number of overlapping genes were observed among groups -1 to -4 and groups -4 to -7 (Fig. 3). A total of 5,394 DEGs were identified in ≥4 groups and were selected and termed common DEGs. Functional enrichment analysis
demonstrated that these genes were involved in the cell cycle, ubiquitin-mediated proteolysis, oxidative phosphorylation and human immunodeficiency virus infection (Table I).

The top 500 DEGs ranked by adjusted P-value were selected, which were used to generate a heatmap for the seven groups. Different expression patterns were observed among the seven groups (Fig. 4).

Relevant miRNAs, TFs and drugs. According to the threshold, 129, 153, 11, 77, 71 and 202 miRNAs were obtained from groups-1 to -7, respectively. A total of 48, 56, 46, 45, 56 and 48 TFs were obtained from groups-1 to -7, respectively. A total of 6, 1, 2, 1, 0, 1 and 2 small molecule drugs were unveiled in groups-1 to -7, respectively. The top 5 miRNAs, TFs and small molecule drugs (ranked by P-value) are listed.

Figure 2. (A) Evaluation of k value; (B) correlation matrix of breast invasive carcinoma groups; (C) heatmap of the 1,500 core genes.
Table I. Biological functions over-represented in the 5,394 differentially expressed genes.

| Source       | Name                                           | Bonferroni-adjusted P-value |
|--------------|------------------------------------------------|-----------------------------|
| KEGG         | Ubiquitin-mediated proteolysis                 | 2.35x10^{-10}              |
| KEGG         | Non-alcoholic fatty liver disease              | 6.50x10^{-10}              |
| KEGG         | Oxidative phosphorylation                      | 6.79x10^{-10}              |
| KEGG         | Cell cycle                                     | 9.26x10^{-10}              |
| KEGG         | RNA transport                                  | 1.69x10^{-9}               |
| KEGG         | Proteasome                                     | 3.30x10^{-9}               |
| KEGG         | Spliceosome                                    | 2.10x10^{-8}               |
| KEGG         | Protein processing in endoplasmic reticulum    | 9.19x10^{-8}               |
| KEGG         | Human T lymphotropic virus type 1 infection   | 9.34x10^{-8}               |
| KEGG         | Ribosome biogenesis in eukaryotes              | 9.34x10^{-8}               |
| KEGG         | DNA replication                                | 1.06x10^{-7}               |
| KEGG         | Shigellosis                                    | 3.96x10^{-7}               |
| REACTOME     | Cell cycle, mitotic                            | 4.29x10^{-7}               |
| REACTOME     | Cell cycle                                    | 5.01x10^{-7}               |
| REACTOME     | Human immunodeficiency virus infection         | 1.18x10^{-6}               |

KEGG, Kyoto Encyclopedia of Genes and Genomes.

Figure 3. Venn diagram showing the overlapping of differentially expressed genes in (A) groups-1 to -4 and (B) groups-4 to -7.

Figure 4. Heatmap of top 500 differentially expressed genes ranked by adjusted P-value. X-axis indicates breast invasive carcinoma samples from groups-1 to -7, whereas Y-axis indicates the 500 genes.

in Table II. Numerous TFs were observed in >1 group, including Sp1 transcription factor and DAN domain BMP antagonist family member 5. In addition, some TFs were unique to certain groups, including MYCN proto-oncogene, bHLH transcription factor in group-7 and cAMP responsive element binding protein 1 (CREB)1 in group-4. Furthermore, different small molecule drugs were revealed between the groups.

**PPI network.** PPIs were identified among the 5,394 DEGs; PPIs with a Pearson’s correlation coefficient >0.5 were selected and seven PPI networks were constructed. The PPI network
for group-1 contained 711 interactions and 748 genes. The PPI network for group-2 included 197 interactions and 256 genes. The PPI network for group-3 included 473 interactions and 533 genes. The PPI network for group-4 included 207 interactions and 258 genes. The PPI network for group-5 included 382 interactions and 453 genes. The PPI network for group-6 included 774 interactions and 830 genes. The PPI network for group-7 included 416 interactions and 463 genes.

Degree was calculated for each node and the top 10 hub genes of the seven PPI networks are listed in Table III. Some hub genes were unique to certain groups, including RB transcriptional corepressor 1 (RB1) from group-1, inhibitor of nuclear factor (NF)-κB kinase subunit γ (IKBKG) from group-2, transporter 1, ATP binding cassette subfamily B member from group-4, small nuclear ribonucleoprotein polypeptide E from group-5, and CREB binding protein from group-6.

Survival analysis. A total of 101 cases succumbed to BRCA, as follows: 3 cases from group-1, 32 from group-2, 10 from group-3, 38 from group-4, 11 from group-5, 1 from group-6 and 6 from group-7. The survival analysis demonstrated that groups-2, -4 and -5 had similar survival curves (Fig. 5A). Therefore, these groups were combined into m-group-2, whereas the remaining groups were combined into m-group-1. A significant difference was observed between the combined two groups (P=0.0484; Fig. 5B). According to the available data, no common features in m-group-1 and m-group-2, including gene expression patterns and clinical features, were observed.

Discussion

Expression data from 1,073 BRCA samples and 99 normal samples were analyzed in the present study. The BRCA samples...
were divided into seven groups, and a total of 5,394 common DEGs were obtained. The identified DEGs were involved in the cell cycle, ubiquitin-mediated proteolysis and oxidative phosphorylation. Subsequently, PPI networks were constructed for the DEGs and hub genes were selected.

A combination of differential and network analyses was useful in identifying critical genes. Some of the identified hub genes have previously been implicated in breast cancer. TNF receptor-associated factor 2 mediates the signal transduction from members of the TNF receptor superfamily and serves a role in regulation of breast cancer cell invasion (28,29). Spleen associated tyrosine kinase (SYK) is a tumor suppressor, the expression of which is often absent or reduced in invasive breast cancer tissues (30,31). SYK may exert its function through integrin-mediated protein tyrosine phosphorylation (32). Proliferating cell nuclear antigen is considered a potential biomarker of BRCA (33). Polypyrimidine tract-binding protein 1 (PTBP1) has been reported to serve a role in the maintenance of breast cancer cell growth and malignant properties (34). The stability of PTBP1 is increased in breast cancer cell lines compared with in matched controls (35). FYN proto-oncogene, Src family tyrosine kinase is a member of the protein-tyrosine kinase oncogene family and is implicated in the control of cell growth. In addition, it is considered an important molecule in drug resistance in breast cancer (36), is induced by Ras/phosphoinositide 3-kinase/Akt signaling and is required for enhanced invasion (37). RB1 is a negative regulator of the cell cycle and was the first identified tumor suppressor gene. In addition, RB1 is associated with epithelial-to-mesenchymal transition in triple-negative breast cancer (38); therefore, it may be used to predict drug

Table III. Top 10 hub genes of the seven groups.

| Group | Gene   | Degree |
|-------|--------|--------|
| 1     | TRAF2  | 11     |
|       | SYK    | 10     |
|       | RB110  |        |
|       | CEBPB  | 10     |
|       | CSNK2B | 9      |
|       | PCNA   | 8      |
|       | STAT1  | 8      |
|       | MCM3   | 8      |
|       | COP56  | 8      |
|       | MCM2   | 8      |
| 2     | STAT1  | 6      |
|       | MCM3   | 6      |
|       | MCM7   | 6      |
|       | MCM2   | 6      |
|       | PCNA   | 5      |
|       | IKBKG  | 5      |
|       | PTBP1  | 5      |
|       | SNRPD2 | 5      |
|       | NFKB2  | 5      |
|       | TAP2   | 4      |
| 3     | ACTB   | 14     |
|       | COPS6  | 9      |
|       | LYN7   |        |
|       | NFKB2  | 7      |
|       | MCM3   | 7      |
|       | ARPC4  | 7      |
|       | FYN    | 7      |
|       | PSMB5  | 7      |
|       | SYK    | 6      |
|       | PCNA   | 6      |
| 4     | FYN    | 10     |
|       | LYN7   |        |
|       | PCNA   | 7      |
|       | MCM6   | 7      |
|       | MCM2   | 7      |
|       | STAT1  | 6      |
|       | MCM3   | 6      |
|       | MCM7   | 6      |
|       | TAP1   | 4      |
|       | PSMA3  | 4      |
| 5     | PCNA   | 8      |
|       | SNRPE  | 8      |
|       | SNRPF  | 7      |
|       | SNRPD2 | 7      |
|       | MCM2   | 7      |
|       | TAF1   | 6      |
|       | LSM2   | 6      |
|       | MCM3   | 6      |
|       | MCM6   | 6      |
|       | COPS6  | 6      |

Table III. Continued.

| Group | Gene   | Degree |
|-------|--------|--------|
| 6     | COPS6  | 14     |
|       | TRAF2  | 13     |
|       | ACTB   | 11     |
|       | FYN    | 11     |
|       | C14orf1| 10     |
|       | STAT1  | 9      |
|       | CSNK2B | 9      |
|       | PRPF40A| 9      |
|       | LYN8   |        |
| 7     | FYN    | 11     |
|       | COPS6  | 9      |
|       | ACTB   | 9      |
|       | LYN8   |        |
|       | SNRPD2 | 8      |
|       | SNRF   | 7      |
|       | CSNK2B | 7      |
|       | MCM2   | 7      |
|       | PCNA   | 6      |
|       | PSMA3  | 6      |
response (39) and long-term survival (40). NFKB2 is a subunit of the transcription factor complex NF-kB, whereas IKBK was identified in the present study. miR-130a (42), miR-26a (43) and miR-30a (44) have been reported to suppress breast cancer cell proliferation and migration. Furthermore, miR-340 inhibits breast cancer cell migration and invasion through targeting the oncogene c-Met (45). Conversely, upregulated miR-30a in breast cancer promotes tumor metastasis by targeting phosphatase and tensin homolog and activating Wnt/β-catenin signaling (46). Furthermore, miR-506 has been reported to regulate epithelial-mesenchymal transition in breast cancer cell lines (47), whereas miR-214 enhances the invasive ability of breast cancer cells by targeting p53 (48). The TF early growth response 3 is involved in the estrogen-signaling pathway in breast cancer cells (49). E2F transcription factor 1 is a proliferative marker of breast neoplasia (50). In addition, ELK1, ETS transcription factor, is a member of the ETS oncogene family, and is implicated in breast cancer cell survival (51). These factors may be used to develop novel therapies for the treatment of breast cancer. In addition, two small molecule drugs that are currently used to treat BRCA, were identified to be associated with the BRCA DEGs: Bortezomib (52,53) and sunitinib (54), thus suggesting the reliability of the DEGs.

In the present study, the two combined BRCA groups exhibited a significant difference in survival rate. Therefore, a comparative analysis of the two combined groups may disclose prognostic genes associated with breast cancer.

In conclusion, numerous critical genes were identified in BRCA. Further studies regarding these genes may improve understanding regarding the complex molecular mechanisms underlying BRCA and result in the identification of therapeutic targets. The identified relevant miRNAs and TFs in the present study may also provide information that aids future therapy development.

References

1. McGuire A, Brown JA, Malone C, McLaughlin R and Kerin MJ: Effects of age on the detection and management of breast cancer. Cancers (Basel) 7: 908-929, 2015.
2. DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62, 2014.
3. McGuire S: World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International agency for research on cancer, WHO press, 2015. Adv Nutr 7: 418-419, 2016.
4. Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Rashidi B, Singh B, Ozdemirli M and Mueller SC: Progressive marker of breast neoplasia (50). In addition, ELK1, ETS transcription factor, is a member of the ETS oncogene family, and is implicated in breast cancer cell survival (51). These factors may be used to develop novel therapies for the treatment of breast cancer. In addition, two small molecule drugs that are currently used to treat BRCA, were identified to be associated with the BRCA DEGs: Bortezomib (52,53) and sunitinib (54), thus suggesting the reliability of the DEGs.

In the present study, the two combined BRCA groups exhibited a significant difference in survival rate. Therefore, a comparative analysis of the two combined groups may disclose prognostic genes associated with breast cancer.

In conclusion, numerous critical genes were identified in BRCA. Further studies regarding these genes may improve understanding regarding the complex molecular mechanisms underlying BRCA and result in the identification of therapeutic targets. The identified relevant miRNAs and TFs in the present study may also provide information that aids future therapy development.

References

1. McGuire A, Brown JA, Malone C, McLaughlin R and Kerin MJ: Effects of age on the detection and management of breast cancer. Cancers (Basel) 7: 908-929, 2015.
2. DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62, 2014.
3. McGuire S: World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International agency for research on cancer, WHO press, 2015. Adv Nutr 7: 418-419, 2016.
4. Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Rashidi B, Singh B, Ozdemirli M and Mueller SC: Progressive marker of breast neoplasia (50). In addition, ELK1, ETS transcription factor, is a member of the ETS oncogene family, and is implicated in breast cancer cell survival (51). These factors may be used to develop novel therapies for the treatment of breast cancer. In addition, two small molecule drugs that are currently used to treat BRCA, were identified to be associated with the BRCA DEGs: Bortezomib (52,53) and sunitinib (54), thus suggesting the reliability of the DEGs.

In the present study, the two combined BRCA groups exhibited a significant difference in survival rate. Therefore, a comparative analysis of the two combined groups may disclose prognostic genes associated with breast cancer.

In conclusion, numerous critical genes were identified in BRCA. Further studies regarding these genes may improve understanding regarding the complex molecular mechanisms underlying BRCA and result in the identification of therapeutic targets. The identified relevant miRNAs and TFs in the present study may also provide information that aids future therapy development.

References

1. McGuire A, Brown JA, Malone C, McLaughlin R and Kerin MJ: Effects of age on the detection and management of breast cancer. Cancers (Basel) 7: 908-929, 2015.
2. DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62, 2014.
3. McGuire S: World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International agency for research on cancer, WHO press, 2015. Adv Nutr 7: 418-419, 2016.
4. Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Rashidi B, Singh B, Ozdemirli M and Mueller SC: Progressive marker of breast neoplasia (50). In addition, ELK1, ETS transcription factor, is a member of the ETS oncogene family, and is implicated in breast cancer cell survival (51). These factors may be used to develop novel therapies for the treatment of breast cancer. In addition, two small molecule drugs that are currently used to treat BRCA, were identified to be associated with the BRCA DEGs: Bortezomib (52,53) and sunitinib (54), thus suggesting the reliability of the DEGs.

In the present study, the two combined BRCA groups exhibited a significant difference in survival rate. Therefore, a comparative analysis of the two combined groups may disclose prognostic genes associated with breast cancer.

In conclusion, numerous critical genes were identified in BRCA. Further studies regarding these genes may improve understanding regarding the complex molecular mechanisms underlying BRCA and result in the identification of therapeutic targets. The identified relevant miRNAs and TFs in the present study may also provide information that aids future therapy development.

References

1. McGuire A, Brown JA, Malone C, McLaughlin R and Kerin MJ: Effects of age on the detection and management of breast cancer. Cancers (Basel) 7: 908-929, 2015.
2. DeSantis C, Ma J, Bryan L and Jemal A: Breast cancer statistics, 2013. CA Cancer J Clin 64: 52-62, 2014.
3. McGuire S: World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International agency for research on cancer, WHO press, 2015. Adv Nutr 7: 418-419, 2016.
4. Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Rashidi B, Singh B, Ozdemirli M and Mueller SC: Progressive marker of breast neoplasia (50). In addition, ELK1, ETS transcription factor, is a member of the ETS oncogene family, and is implicated in breast cancer cell survival (51). These factors may be used to develop novel therapies for the treatment of breast cancer. In addition, two small molecule drugs that are currently used to treat BRCA, were identified to be associated with the BRCA DEGs: Bortezomib (52,53) and sunitinib (54), thus suggesting the reliability of the DEGs.

In the present study, the two combined BRCA groups exhibited a significant difference in survival rate. Therefore, a comparative analysis of the two combined groups may disclose prognostic genes associated with breast cancer.

In conclusion, numerous critical genes were identified in BRCA. Further studies regarding these genes may improve understanding regarding the complex molecular mechanisms underlying BRCA and result in the identification of therapeutic targets. The identified relevant miRNAs and TFs in the present study may also provide information that aids future therapy development.
31. Toyama T, Iwase H, Yamashita H, Hara Y, Omoto Y, Sugihara H, Zhang Z and Fuji Y: Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett 189: 97-102, 2003.

32. Zhang X, Shrikhande U, Alicie BM, Zhou Q and Grahlien RL: Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol Cancer Res 7: 634-644, 2009.

33. Malkas LH, Herbert BS, Abdel-Aziz W, Dobrolecki LE, Liu Y, Agarwal B, Hoelz D, Badve S, Schnaper L, Arnold RJ, et al: A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci USA 103: 19472-19477, 2006.

34. He X, Arslan AD, Ho TT, Yuan C, Stampfer MR and Beck WT: Involvement of polyplymidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties. Oncogene 3: e84, 2014.

35. Arslan AD, Asztalos S, Stampfer M, Tonetti D, He X and Beck WT: PTBP1 stability is increased in ovarian and breast cancer cell lines compared to matched controls. Cancer Res 73: 3201, 2013.

36. Elias D, Vever H, Lenkholm AV, Gjerstorff MF, Yde CW, Lykkefeldt AE and Ditzel HJ: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy. Oncogene 34: 1919-1927, 2015.

37. Yadav V and Denning MF: FYN is induced by Ras/PI3K/Akt signaling and is required for enhanced invasion/migration. Mol Carcinog 50: 346-352, 2011.

38. Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JJ, Egan SE, Perou CM and Zackmesnhaus E: RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 10: 1563-1570, 2011.

39. Robinson TJ, Liu JC, Vizeacoumar F, Sun T, Maclean N, Egan SE, Schimmer AD, Datti A and Zackmesnhaus E: RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One 8: e78641, 2013.

40. Chano T, Ikebuchi K, Tomita Y, Jin Y, Inaji H, Ishitobi M, Teramoto K, Ochi Y, Tameno H, Nishimura I, Chano T, Ikebuchi K, Tomita Y, Jin Y, Inaji H, Ishitobi M, et al: RB1CC1 together with RB1 and p53 predicts long-term survival in Japanese breast cancer patients. PLoS One 5: e15737, 2010.

41. Lerebours V, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R and Bieche I: NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 8: 41, 2008.

42. Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long G and Yang K: MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. Int J Clin Exp Pathol 8: 384-393, 2015.

43. Liu P, Tang H, Chen B, He Z, Deng M, Wu M, Liu X, Yang L, Ye F and Xie X: miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Lett 357: 392-395, 2015.

44. Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J, Cheng L, Fan Z, Yuan B, Tian P, et al: miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. Biochem Biophys Res Commun 445: 314-319, 2014.

45. Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, Zhao JJ, Mao SS, Zhang GH, Xu XC and Zhang N: miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer 117: 2842-2852, 2011.

46. Ma F, Zhang J, Zhong L, Wang L, Liu Y, Wang Y, Peng L and Guo B: Upregulated microRNA-30a1 in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling. Gene 535: 191-197, 2014.

47. Arora H, Qureshi R and Park WY: miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS One 8: e64273, 2013.

48. Wang F, Lu P, Liu X, Zhu M and Qiu X: MicroRNA-214 enhances the invasion ability of breast cancer cells by targeting p53. Int J Mol Med 35: 1395-1402, 2015.

49. Inoue A, Omoto Y, Yamaguchi Y, Kiyama R and Hayashi SI: Transcription factor EGR3 is involved in the estrogen-signaling pathway in breast cancer cells. J Mol Endocrinol 32: 649-661, 2004.

50. Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babj J, Guo X and Klein-Szanto AJ: E2F-1: A proliferative marker of breast neoplasia. Cancer Epidemiol Biomarkers Prev 9: 395-401, 2000.

51. Booy EP, Henson ES and Gibson SB: Epidermal growth factor receptor regulates Mcl-1 expression through the MAPK-Elk-1 signaling pathway contributing to cell survival in breast cancer. Oncogene 30: 2367-2378, 2011.

52. Engel RH, Brown JA, Von Roenn JH, O’Regan RM, Bergan R, Badve S, Rademaker A and Gradishar WJ: A phase II study of single agent bortezomib in patients with metastatic breast cancer: A single institution experience. Cancer Invest 25: 733-737, 2007.

53. Schmid P, Kühnhardt D, Kiewe P, Lehmann Dehre S, Schippering W, Greil R, Lange W, Preiss J, Niederle N, Brossart P, et al: A phase I/II study of bortezomib and capcitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 19: 871-876, 2008.

54. Burstern HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, et al: Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 26: 1810-1816, 2008.